Exhibit 99.1
VASCULAR BIOGENICS LTD.
8 HaSatat St. Modi’in, Israel Tel. +972-8-9935000Fax. +972-8-9935001
________________________________
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
TO BE HELD ON DECEMBER 13, 2018
________________________
Dear Vascular Biogenics Ltd. Shareholders:
We cordially invite you to attend an Annual -General Meeting of shareholders of Vascular Biogenics Ltd., or the Company, to be held at 4 p.m. (Israel time) on December 13, 2018, at our offices at 8 HaSatat St. Modi’in, Israel (the “Meeting”).
The Meeting is being called for the following purposes:
| (1) | To approve the nomination of Dr. Bennett M. Shapiro, Prof. Dror Harats, Prof. Ruth Arnon, Ms. Ruth Alon, Dr. Shmuel (Muli) Ben Zvi, Dr. Ron Cohen, Mr. David Hastings and Dr. Susan Kelley to the Board of Directors of the Company (the “Board”), to serve until the next annual general meeting of shareholders of the Company, until each of their successors is duly appointed and qualified, or until any of their earlier resignation or removal (voting will take place in relation to each director nominee separately); and | |
| (2) | To approve the re-appointment of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, as the Company’s independent registered public accounting firm for the year ending December 31, 2018, and until the next annual general meeting of shareholders of the Company and authorize the Board (with power of delegation to its audit committee) to fix the said independent registered public accounting firm’s remuneration in accordance with the volume and nature of its services; and | |
| (3) | To approve the grant of options and performance share units under the Company’s 2014 Employee Share Ownership and Option Plan (the “2014 Plan”) according to the standard agreements as follows: (i) grant of an option to purchase 80,000 of our ordinary shares and 40,000 performance share units to Prof. Harats; (ii) grant of an option to purchase 20,000 of our ordinary shares to Dr. Shapiro; (iii) grant of an option to purchase 12,000 of our ordinary shares to Mr. Serlin; (iv) grant of an option to purchase 12,000 of our ordinary shares to Dr. Cohen; (v) grant of an option to purchase 12,000 of our ordinary shares to Prof. Arnon; (vi) grant of an option to purchase 12,000 of our ordinary shares to Ms. Alon; (vii) grant of an option to purchase 30,000 of our ordinary shares to Mr. Hastings; (viii) grant of an option to purchase 30,000 of our ordinary shares to Dr. Kelley; and (ix) grant of an option to purchase 30,000 of our ordinary shares to Dr. Ben Zvi, each of which shall vest in the manner approved by the Compensation Committee and the Board. | |
| (4) | To approve the increase of Prof. Harats’ monthly base salary to NIS 85,600. | |
| (5) | To approve the extension of the expiry term of all vested options of Mr. Philip Serlin to 24 months following the termination date of his service as a member of the Board. |
At the Meeting, we will also present and discuss our annual audited consolidated financial statements for the year ended December 31, 2017, as previously made available to our shareholders as part of our Form 20-F filed with the Securities and Exchange Commission and available atwww.sec.gov and in the “Investor Relations” section of our Company’s website, www.vblrx.com. We will also transact such other business as may properly come before the Meeting or any adjournment thereof.
The affirmative vote of the holders of a majority of the voting power represented at the Meeting in person or by proxy and voting thereon (which excludes abstentions) is necessary for the approval of each of the proposals.
The proposals and details with respect to the Meeting are described more fully in the enclosed proxy statement, which the Company will send (together with this notice) to its shareholders, which we urge you to read in its entirety. This notice, proxy statement and related proxy card are also being furnished to the U.S. Securities and Exchange Commission, or the SEC, in a report on Form 6-K, which may be obtained for free from the SEC’s website at www.sec.gov or at the Company’s website — at www.vblrx.com. The full text of the proposed resolutions, together with the form of proxy card for the Meeting, may also be viewed beginning on October 16, 2018 at the registered office of the Company, 8 HaSatat St. Modi’in, Israel, upon prior coordination with the Company. Our telephone number at our registered office is +972-8-9935000.
Shareholders of record of shares as of the close of business on November 15, 2018 are entitled to notice of and to vote at the Meeting (with one vote per share held).
Shareholders who are unable to attend the Meeting in person will be requested to complete, date and sign all enclosed proxy cards and return them promptly by mail to the registered office of the Company, 8 HaSatat St. Modi’in, P.O.Box 9141, Israel 7178106, by Fax. +972-8-9935001, or by e-mail to our Company Secretary: amos@vblrx.com. If you are sending your proxy cards to us by mail, the proxy cards must be received at our registered office at least 48 hours prior to the appointed time of the Meeting to be validly included in the tally of shares voted at the Meeting, unless we waive that requirement. Your proxy cards, if properly executed, will be voted in the manner directed by you. Detailed proxy voting instructions will be provided both in the proxy statement and on the proxy cards.
If your ordinary shares are held in “street name”, that is, in a brokerage account or by a trustee or nominee, you may be able to utilize the control number appearing on the voting instruction form to submit your voting instruction to their brokers, trustees or nominees by other means, including via the internet.
| Sincerely, | |
| Dr. Bennett M. Shapiro | |
| Chairman of the Board of Directors |